Category Archives: Topics

Ascendis/Novo Terminate QM Sema Agreement; Novo Cagrisema Switch Study; Dexcom Appoints COO; Arrowhead ARO-DIMER-PA Data; Elvinix/Zealand ZP3022 Licensing Agreement; Lilly Terminates Ph1 Obesity Asset; Medtronic Expands Separation from MiniMed; Tracky Launches 16-Day CGM in India

A series of cardiometabolic-related news items has been observed from Ascendis Pharma, Novo, Dexcom, Arrowhead Pharmaceuticals, Elvinix, Lilly, MiniMed, and Tracky. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo Rebranding; Corbus Topline Ph1b CB1 Data; New Foundayo DTC TV Ads; New Alveus Ph2 Obesity Study; Beta Bionics Patch Pump FDA Clearance; Senseonics Integrates with Beta Bionics’s iLet AID; September CHMP Agenda

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Corbus Pharmaceuticals, Lilly, Alveus Therapeutics, Beta Bionics, Senseonics, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo to Announce Org Changes; Novartis/Ionis Pelacarsen Updates

Two cardiometabolic-related news items have been observed: Novo Nordisk announced a Global Town Hall meeting for its employees ahead of its upcoming CMD (view X post), and Ionis provided additional updates on pelacarsen during the Wells Fargo Healthcare Conference 2026 (view webcast). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Innovent Initiates Ph1 INHBE China-based Study in Obesity; BioLife Receives Patent for Dissolvable Obesity Medicine; Novo’s Semaglutide Approved for MASH in China

Three cardiometabolic-related news items have been observed: Innovent Biologics initiated a Ph1 FIH study of its Q3M/Q6M SC INHBE (view CT.gov record); BioLife received a US patent for its effervescent oral peptide delivery technology (view press release); and Novo Nordisk’s injectable semaglutide received approval from NMPA for the treatment of F2-F3 MASH (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Ascletis FIH Oral Amylin Study; Moonwalk $70M Series B; New Lilly Obesity Asset; Kura Oncology Spins Out Diabetes Business; MannKind Partners for Inhaled GLP-1RA; NodThera Name Change and Topline Ph2 NLRP3i Data

A series of cardiometabolic-related news items has been observed from Ascletis Pharma, Moonwalk Biosciences, Lilly, Kura Oncology/Caspian Therapeutics, MannKind, and NodThera. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Ionis Receives PRV; Modular Medical Signs Contract with US PBM

Two cardiometabolic-related news items have been observed: Ionis Pharmaceuticals received a PRV upon approval of Zanvastro in Alexander Disease (view press release), and Modular Medical contracted with an undisclosed US PBM for its Pivot tubeless patch pump (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

G&L and Menarini Bofanglutide Licensing Agreement; G&L FIH QW Oral GLP-1RA Study; Inventiva NATiV3 LPLV Milestone; Modular Medical Patch Pump Update; Eledon Tegoprubart Updates; Superluminal Series B Financing Round

A series of cardiometabolic-related news items has been observed from Menarini, Gan & Lee Pharmaceuticals, Inventiva, Modular Medical, Eledon Pharmaceuticals, and Superluminal Medicines. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Lilly Orfor Obesity/ORC Prevention Study; NewAmsterdam Alzheimer’s Study; Novartis to Advance IL-6 Inhibitor to Ph3; Wegovy Pill Germany Launch; Pfizer Berobenatide Japan Studies; MiniMed CY Q2 ’26 Earnings; Novo Initiates AMBITION 7

A series of cardiometabolic-related news items has been observed from Lilly, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, MiniMed, and CSPC Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here